Exact Sciences Corporation (EXAS) has experienced a positive trend in recent months, with insider trading activities recorded, including the sale of 5,000 shares by Orville Jacob A and 3,628 shares by Cunningham Everett. Analysts’ opinions on the stock are mixed, with some rating it as a “buy” and others rating it as a “hold.” The stock is trading significantly below its 50-day moving average and 52-week high.
Stock fundamentals reveal that the company’s operating margin is presently at -29.79, and the gross margin is +67.77. The net margin for EXAS stands at -29.91, with an equity return value of -19.80 and -9.80 for asset returns. Additionally, the liquidity ratio stands at 2.38.
Overall, EXAS has seen better performance in recent times. However, investors should take note of the mixed analyst opinions and the current distance of the stock from its 50-day moving average and 52-week high.
Exact Sciences Corporation (EXAS) stock has experienced a positive trend in recent months, with a 3.09% increase in the past week, a 4.68% gain in the past month, and a 27.99% rise in the past quarter. The company’s volatility ratio for the past 30 days is 4.62%, and the simple moving average for the last 20 days is 4.38% for EXAS stock. As of March 22, 2023, the average trading volume of EXAS is 2.57M shares.
According to Barron’s, Exact Sciences Corporation reported “big sales and a surprise profit” on January 9, 2023. Citigroup has listed EXAS as a “Buy,” predicting a price of $90 in the upcoming period. However, Credit Suisse predicted that EXAS would reach a price target of $70, with a “Neutral” rating for EXAS stocks.
The average price predicted by analysts for EXAS is $76.24, which is $9.79 above the current price. The public float for EXAS is 176.12M, and short sellers currently hold a 7.42% ratio of that float.
Despite a stumble in the market, EXAS is trading at 2.45% from the 50-day moving average, and the stock is currently +40.81% higher over the past 50 days. Over the last 5 trading sessions, EXAS rose by +3.09%. Insider trading information was not included in the original text.
Exact Sciences Corporation (EXAS) has recently experienced several insider trading activities. Orville Jacob A sold 5,000 shares for $65.00 on March 03 and now holds 11,423 shares valued at $325,000. Cunningham Everett, the Chief Commercial Officer of EXAS, sold 3,628 shares at $62.01 on March 01, and currently holds 22,703 shares valued at $224,972.
According to stock fundamentals, the company’s operating margin is presently at -29.79, while the gross margin is +67.77. The net margin for EXAS stands at -29.91, with an equity return value of -19.80 and -9.80 for asset returns. Additionally, the liquidity ratio stands at 2.38.
Overall, analysts have a mixed opinion on EXAS, with some rating it as a “buy” and others rating it as a “hold.” It’s important to note that the stock is trading significantly below its 50-day moving average and its 52-week high.
Don’t miss interesting posts on Famousbio
